Introduction

▼
Taurine and magnesium are eff ective supplements to prevent arrhythmias and protect the myocardium [ 1 -3 ] . Taurine blocks voltage-dependent L-type calcium channels, which reduces calcium channel current density and decreases pathological and drug-induced arrhythmia incidences [ 4 , 5 ] . Taurine produces a positive inotropic eff ect by increasing intracellular Ca 2 + by activating the taurine-Na + co-transporter and Na + -Ca 2 + exchanger [ 6 , 7 ] . Magnesium, a natural calcium antagonist, inhibits Ca 2 + infl ux through both L-type and N-type calcium channels [ 8 ] . Extracellular magnesium signifi cantly inhibits Ca 2 + infl ux, when extracellular calcium levels fall below physiological concentrations [ 9 ] . Our laboratory has previously shown that the combined use of taurine and magnesium was superior to either alone to treat arrhythmias induced by ischemia/reperfusion. Based on these fi ndings, we chemically synthesized a taurine-magnesium coordination compound (TMCC, • ▶ Fig. 1 ). Over the years, TMCC has become recognized as a specifi c and selective antiarrhythmic agent with a low toxicity profi le. Arrhythmias induced by electrical stimulation, epinephrine, aconitine, stophanthin G, or cesium choride have all been blocked Because of the known anti-arrhythmic eff ects of taurine-magnesium coordination compound (TMCC), the aim of the present study was to explore the electrophysiological eff ects of TMCC on hypoxia/reoxygenation (H/R)-induced arrhythmias in rat ventricular myocytes. Sodium current ( I Na ), the L-type calcium current ( I Ca,L ), and the transient outward potassium current ( I to ) were evaluated using whole-cell patchclamp recordings in rat ventricular myocytes following H/R injury. The H/R group signifi cantly decreased sodium currents, while L-type calcium currents and transient outward potassium currents was signifi cantly increased (all p < 0.01). TMCC (200 and 400 μM) prevented abnormal sodium currents induced by H/R by inhibiting steady-state inactivation. It also counteracted abnormal L-type calcium currents induced by H/R by inhibiting steady-state activation and facilitating steady-state inactivation. In addition, it mitigated abnormal transient outward potassium currents induced by H/R by inhibiting steady-state activation. TMCC prevents H/Rinduced arrhythmias in rat ventricular myocytes by modifying ion channel function. by the committee. Wistar rats of either sex, weighing 200-250 g (grade II, certifi cate no. 2008-0002) were purchased from the Experimental Animal Center of China Tianjin Medical University. Data was acquired from at least n = 6 myocytes from 1 rat for each experiment.
Drugs
TMCC was kindly provided by the Department of Chemistry, Tianjin Medical University (batch no. 100031) and was dissolved in distilled water to prepare a stock solution (200 mM). The stock solution was diluted with Tyrode's solution for the patch clamp studies.
Cell preparation
As described previously, we isolated single ventricular myocytes from adult rat left ventricles by enzymatic dissociation [ 11 ] . Briefl y, rats were anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg · kg − 1 ) and heparin (300 U · kg − 1 ). The rat heart was excised, placed on a Langendorff apparatus, and perfused in a retrograde fashion with oxygenated ice-cold Ca 2 + -free Tyrode's solution through the aorta at a perfusion rate of 4 ml · min − 1 for 5 min. The heart was subsequently perfused with Ca 2 + -free Tyrode's solution with 34 μM CaCl 2 and 300 mg · L − 1 collagenase II at 37 °C for 12 min. The left ventricle was removed, cut into 1 mm pieces, and placed in Krebs solution. Single myocytes were harvested by passing the single cell suspension through a nylon mesh with pore size of 200 μm. The cells were rested by incubating in Krebs solution at room temperature for 1-3 h. The Ca 2 + concentration in the Krebs solution was gradually increased to 1 mM before the experiment.
Whole cell patch clamp experiments
For whole cell patch clamp experiments, the isolated ventricular myocyte suspension was pipetted into a perfusion chamber that was set on the stage of an inverted microscope (Olympus IX51, Tokyo, Japan). Glass microelectrodes were made as described previously [ 11 ] . The ion currents, including sodium, L-type calcium, and transient outward potassium currents, were recorded with an Axopatch 700B amplifi er (Axon Instruments, Foster City, CA, USA). The recordings were digitized at 2-10 kHz with the Digit Data 1440A analogue-to-digital converter (Axon Instruments), and the pCLAMP 10.0 software (Axon Instruments) was used to acquire data and analyze traces for the voltage clamp protocols. The whole-cell series resistance was compensated to > 80 %, and the current traces were presented as current density (pApF − 1 ). All experiments were performed at room temperature (23 ± 1 °C). Using the above protocols, whole cell I Na was tested at potentials ranging from − 120 to + 30 mV, at 10 mV increments. The I Na was calculated as the diff erence between peak inward current and the holding current level. Steady-state activation curves of I Na were derived from the current-voltage relationship and were fi tted according to the Boltzmann equation. The voltage dependent steady-state inactivation of I Na was defi ned by applying a 50 ms conditioning pulse, ranging from − 150 mV to + 30 mV in 10 mV increments, followed by a 25 ms test pulse to − 30 mV. The data were fi tted using the Boltzmann distribution equation. Whole cell I Ca,L was elicited from a holding potential of − 40 mV and tested with potentials ranging from − 40 to + 60 mV, in 10 mV increments. I Ca,L was calculated as the diff erence between peak inward and holding current. The steady-state activation curve of I Ca,L was derived from the current-voltage relationships and fi tted to the Boltzmann equation. The voltage dependent steady-state inactivation of I Ca,L was determined by applying a 1 000 ms conditioning pulse ranging from -40 to + 20 mV, in 10 mV increments, followed by a 150 ms test pulse to 0 mV, with a holding potential of − 40 mV. The data were fi tted to the Boltzmann distribution equation. Whole cell I to was elicited from a holding potential of − 50 mV, with test potentials ranging from − 50 to + 65 mV, in 5 mV increments. The outward peak amplitude was I to , which was the major repolarizing potassium current in rat ventricular myocytes. The steady-state activation curve of I to was derived from the currentvoltage relationship and fi tted according to the Boltzmann equation. The voltage dependent steady-state inactivation of I to was calculated by applying 500 ms prepulses from − 120 to + 30 mV prior to pulsing to a Vm of + 60 mV. Steady-state inactivation curves were constructed by normalizing the measured I to after each prepulse ( I / I max) and plotting the values against the prepulse voltage. The curves were fi tted to the Boltzmann equation to derive steady-state inactivation parameters V 1/2 and k. To record the sodium current, cadmium chloride (0.3 mM) was added to the external solution to block the I Ca-L current, and the maximum sodium current ( I Na,max ) was observed at − 60 mV. To record the calcium current, the magnitude of I ca,L was measured as the peak inward current and the maximum calcium current ( I ca,L,max ) was observed at 15 mV. To record transient outward potassium currents, 0.2 mM Cd 2 + and 0.2 μM Ba 2 + were used to block I ca,L and I k1 , respectively, the maximum transient outward potassium current ( I to,max ) was observed at 50 mV. The standard bath solution was replaced with a bath solution fi lled with N 2 to simulate hypoxia. After 15 min of hypoxia, the N 2 bath solution was replaced with a bath solution fi lled with O 2 to simulate reperfusion. The change in densities of I Na,max , I ca,L,max and I to,max were measured after single ventricular myocytes were exposed to H/R for 10 min. TMCC was administered after exposed to H/R and the I Na,max , I ca,L,max and I to,max were measured 10 min after treatment.
Statistical analysis
Data were presented as mean ± standard error of the mean. Curve fi tting was made using pCLAMP 10.0 (Axon Instruments) or software Origin 6.0 (Microcal Software, Northampton, MA, USA). Statistical signifi cance was analyzed using a 2-tailed paired Student's t -test for comparisons of 2 means or analysis of variance (ANOVA) for comparison of multiple means. A P value < 0.05 was considered statistically signifi cant.
Results
▼ TMCC prevented abnormal sodium channels induced by H/R in rat ventricular myocytes
As shown in • ▶ 
TMCC prevented abnormal L-type calcium channels induced by H/R in rat ventricular myocytes
As shown in • ▶ Table 2 , at a 10 mV test pulse, the calcium current density increased from − 3.35 ± 0.62 pApF − 1 to − 5.69 ± 0.25 pApF − 1 (n = 6 per group, P < 0.01 vs. control). Following H/R injury, the peak inward calcium currents increased signifi cantly by 41 % (p < 0.05 vs. control). TMCC or amiodarone restored the abnormal calcium currents by increasing the currents from 
TMCC prevented abnormal transient outward potassium channels induced by H/R in rat ventricular myocytes
As shown in • ▶ Table 3 , at a 50 mV test pulse, the I to,max density was increased from 8.40 ± 0.66 pApF − 1 to 13.50 ± 0.41 pApF − 1 (n = 6 per group, P < 0.01 vs. control). Following H/R injury, the peak current density of the transient outward potassium currents was signifi cantly increased by 38 %. TMCC (at the 200 and 400 μM concentrations) or amiodarone prevented the increase Table 1 Eff ects of taurine-magnesium coordination compound (TMCC) and amiodarone on the currents, steady-state activation and inactivation of abnormal sodium channel induced by hypoxia/reoxygenation (H/R) in rat isolated ventricular myocytes. Fig. 4g, h . The H/R group shifted the half activation potential from 25.51 ± 1.58 mV to 21.80 ± 1.03 mV (n = 6, P < 0.01 vs. control), but the slope parameter (κ) was not signifi cantly changed. TMCC or amiodarone shifted the half activation potential from 21.80 ± 1.03 mV to 23.33 ± 2.92 mV and 27.04 ± 0.60 mV for TMCC and to 24.17 ± 1.06 mV for amiodarone (n = 6, P < 0.01 vs. H/R), but the slope parameter (κ) was not signifi cantly changed. The half inactivation potential and the slope parameter (κ) were also not signifi cantly changed between the H/R group and any of the drug treatment groups.
Groups
Discussion
▼ TMCC has been used eff ectively as an antiarrhythmic agent in vivo. The mechanisms underlying its actions, however, have not been fully described. The major fi ndings of the current study were TMCC prevented abnormal sodium channel, L-type calcium channel and transient outward potassium channel induced by H/R in single rat ventricular myocytes. Ischemia/reperfusion injury is known to stimulate structural and functional remodeling of the left ventricle. This remodeling enhances the arrhythmic potential of the myocardium and increases the chance of sudden cardiac death. Both the ischemic and reoxygenation phases perturb normal cardiac myocyte function. Previous studies have assigned roles for K + channels, voltage-dependent L-type Ca 2 + channels, Na + /Ca 2 + exchanger, and sarcoplasmic reticulum Ca 2 + -ATPase pump, and ryanodine receptors [ 14 -19 ] . Our previous studies showed that TMCC could inhibit sodium currents and transient outward potassium currents, concomitant with a moderate increase in L-type calcium currents [ 11 ] . From that study, we concluded that I Na , I ca,L , and I to may be key factors involved in the development arrhythmias. Here, we extend the previous study to determine the eff ects of TMCC on these abnormal channels induced hypoxia/ reoxygenation. The excitability of cardiac ventricular myocytes is critically regulated by the voltage-gated Na + channel. As such, the voltagegated Na + channel is a primary target of several neurotoxins as well as therapeutic agents. Therapeutic agents that have been shown to be effi cacious against the voltage-gated Na + channel include quinidine, lidocaine, and phenytoin [ 20 ] . Our previous study showed that I Na was blocked by TMCC in a concentrationdependent manner, and the eff ects of TMCC (400 μM) were equal to that of amiodarone. TMCC inhibited I Na through retardation of steady-state activation and steady-state inactivation [ 11 ] .
Our results showed that sodium currents were signifi cantly decreased by H/R, which shifted steady-state activation curves to the right and inactivation curves to the left. These results suggest that the steady-state activation of the Na + channel was decelerated while the inactivation was accelerated. The H/R group may inhibit I Na by blocking the steady-state activation and facilitating the steady-state inactivation. TMCC or amiodarone restored sodium currents signifi cantly. The eff ect of amiodarone, however, was not as potent as the eff ect of TMCC. After H/R injury, TMCC or amiodarone shifted the steady-state inactivation curves to the right, while TMCC or amiodarone failed to alter the steady-state activation curves, suggesting that the steady-state inactivation of the sodium channel was decelerated. Taken together, these results provide electrophysiological evidence that TMCC prevents abnormal sodium currents induced by H/R by altering the steady-state inactivation kinetics. In ventricular myocytes, the generation of action potentials is facilitated by the L-type Ca 2 + channels under both physiological and pathophysiological conditions [ 21 -23 ] . Our group has previously shown that TMCC increases I Ca,L activity, which has subsequent positive inotropic eff ects [ 12 , 13 ] . In contrast, established anti-arrhythmia drugs operate through a separate mechanism, indicating that TMCC and established drugs will have non-overlapping eff ects. Our results showed that the H/R group significantly increased L-type calcium currents, and this eff ect was blunted by TMCC treatment. The H/R group shifted the steadystate activation curves to the left and shifted inactivation curves to the right, suggesting that the voltage-dependent steady-state activation of L-type Ca 2 + channel was accelerated and inactivation of L-type Ca 2 + channels was decelerated. These data suggested that the H/R group increased I Ca,L by facilitating of steady-state activation and inhibiting of steady-state inactivation. Both doses of TMCC or amiodarone restored abnormal L-type calcium currents by decreasing the eff ect of H/R. TMCC at the 400 μM dose showed eff ects similar to that of amiodarone. Following H/R injury, TMCC or amiodarone shifted the steadystate activation curves to the right and shifted the steady-state inactivation curve to the left, suggesting that the steady-state activation of the L-type calcium channel was decelerated and inactivation of the L-type calcium channel was accelerated. Our results provide electrophysiological evidence that TMCC prevents abnormal L-type calcium currents induced by H/R by inhibiting steady-state activation and facilitating steady-state inactivation. I to is the predominant repolarizing potassium current in rat ventricular myocytes [ 24 ] . Following depolarization, cardiac I to channels activate and inactivate rapidly, and this response is necessary to maintain the resting membrane potential [ 24 ] . Depolarization is a key mechanism whereby ventricular arrhythmias in induced in pathophysiological setting, and preventing abnormal depolarization is the major target of Class III antiarrhythmic drugs [ 25 ] . Being able to inhibit I to channels could potentially be therapeutically effi cacious to prevent or suppress reentrant arrhythmias [ 26 -28 ] . The result of the present study showed that transient outward potassium currents were signifi cantly increased by H/R. The H/R group shifted steady-state activation to the left, while failed to alter the steadystate inactivation curves, suggesting that the steady-state activation of I to channel was accelerated. These data suggested that the H/R group increased I to through facilitation of steady-state activation. TMCC or amiodarone restored transient outward potassium currents signifi cantly, which were increased by H/R. The eff ect of TMCC was equivalent to that of amiodarone. After H/R injury, TMCC and amiodarone shifted the steady-state activation curves to the right and failed to alter the steady-state inactivation curves, suggesting that the steady-state activation was decelerated. Our study provides electrophysiological evidence that TMCC prevents abnormal transient outward potassium cur- rents induced by H/R by blocking steady-state activation at relatively higher concentrations. It is important to note that our study did not distinguish between the fast ( I to ,f) and slow ( I to ,s) components, and diff erences between these channels should be evaluated in future studies.
In conclusion, the results of this study demonstrate that TMCC can signifi cantly relieve the eff ect of hypoxia/reoxygenation by modifying sodium, L-type calcium, and transient outward potassium channels. The predominant eff ect was to reverse the ionic balance in ventricular myocytes disrupted by H/R. Meanwhile, compared with amiodarone, the eff ect of TMCC prevented abnormal sodium currents induced by H/R was more potent than the eff ect of amiodarone. TMCC, accordingly, may be used as a multi-target antiarrhythmic drug in the future and a useful agent to prevent arrhythmias in the setting of ischemia and reperfusion.
